Welcome
Annual General Meeting of Carl Zeiss Meditec AG
Thursday, March 26, 2026
2,227.6
million Euro revenue in fiscal year 2024/25
257.7
Mio. Euro EBITA* in fiscal year 2024/25
+4%
EBITA*-margin in fiscal year 2024/25
*Earnings before interest, taxes and amortization of intangible assets from the purchase price allocation
467.0
million euros in revenue in the first quarter of 2025/26
-4.8%compared to the previous year
8.1mio. euros in EBITA
CIRRUS®PathFinderTM
AI-based deep learning tool supports OCT interpretation in ophthalmic diagnostics
CONVIVO®In Vivo Pathology Suite
Provides real-time information on tissue microstructure through consultations based on digital images
Our commercial strategy focuses on delivering value to customers worldwide:
We understand local needs, develop tailored offerings, and scale them efficiently - to drive sustainable growth and build long-term customer relationships.
Magnus Reibenspiess Chief Commercial Officer
KINEVO®900 S
Further development of the successful ZEISS KINEVO 900 platform
PENTERO®800 S
ZEISS PENTERO platform redesigned for the digital world
ILM-Blue®by DORC
Vital dye for staining the inner limiting membrane of the retina
Dr. Ananth Sastry, MD, Cleveland Clinic, Ohio
AT LISA®809
In February 2026, ZEISS received a license in China for the new model of this bifocal intraocular lens.
©Deutscher Zukunftspreis / Ansgar Pudenz
©Deutscher Zukunftspreis / Ansgar Pudenz
ZEISS EUV Lithographie
Winner of
Deutscher Zukunftspreis 2020
ZEISS KINEVO 900
Circle of the Best
Deutscher Zukunftspreis 2020
©Deutscher Zukunftspreis / Ansgar Pudenz
©Deutscher Zukunftspreis / Ansgar Pudenz
ZEISS Lattice Lightsheet 7
Winner of
Deutschen Zukunftspreis 2022
ZEISS VisuMax & ZEISS SMILE
Circle of the Best
Deutschen Zukunftspreis 2025
0.55
Euro dividend per share
Thank you!

